Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DEFERASIROX vs DELANDISTROGENE MOXEPARVOVEC-ROKL: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DEFERASIROX vs DELANDISTROGENE MOXEPARVOVEC-ROKL: Safety Overview

Metric DEFERASIROX DELANDISTROGENE MOXEPARVOVEC-ROKL
Total FAERS Reports 11,322 196
Deaths Reported 2,661 6
Death Rate 23.5% 3.1%
Hospitalizations 4,008 102
Average Patient Age 49.8 yrs 8.7 yrs
% Female Patients 50.1% 2.4%
FDA Approval Date Apr 11, 2025 N/A
Manufacturer AvKARE Sarepta Therapeutics, Inc.
Route ORAL INTRAVENOUS
Marketing Status Prescription N/A